A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by electro-encephalography (EEG)
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Lacosamide (Primary) ; Pregabalin (Primary) ; Tapentadol (Primary)
- Indications Pain
- Focus Pharmacodynamics
- Acronyms IMI2-PainCare-BioPain-RCT3
Most Recent Events
- 22 Jul 2022 This trial has been Discontinued in Italy,according to European Clinical Trials Database record.
- 13 Jul 2022 This trial has been completed in Belgium (End date: 30 Jun 2022), according to European Clinical Trials Database record.
- 17 Jun 2021 According to results published in the Trials, recruitment is expected to end before 31/12/2021.